Tech Company Financing Transactions
Beactica Therapeutics Funding Round
On 2/17/2026, Beactica Therapeutics received $2.9 million in funding from European Innovation Council Fund.
Transaction Overview
Company Name
Announced On
2/17/2026
Transaction Type
Debt
Amount
$2,900,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding enables us to complete our IND-enabling studies and move toward first-in-human trials, bringing this first-in-class LSD1-CoREST degrader closer to patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Rapsgatan 7, Uppsala Business Park
Uppsala 7, 754 50
Sweden
Uppsala 7, 754 50
Sweden
Phone
Website
Email Address
Not Recorded
Overview
Beactica's vision is to create novel medicines that improve the prospects for patients suffering from life-threatening diseases. We create novel medicines that will benefit patients across the world. We will bring hope to those patients and their families. We will impress the giants of the pharmaceutical industry with our scientific breakthroughs. We will succeed in selecting and targeting key disease proteins of vital importance for disease progression.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Per Källblad
Browse more venture capital transactions:
Prev: 2/17/2026: Utility Global venture capital transaction
Next: 2/17/2026: Certivo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs